Itaalia - itaalia - Ministero della Salute

santiveri sa -

Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

a.vogel ag - sabal extractum ethanolicum spissum - prostata-capsule - estratto di sabal ethanolicum di spessore 320 mg, der: 9.0-12.0:1, auszugsmittel ethanolum 96 % v/v, excipiens per la capsula. - in caso di incipiente prostatabeschwerden - phytoarzneimittel

Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

perrigo schweiz ag - cucurbitae peponis seminis extracum spissum (cucurbita pepo l. convar. citrullina i. greb. var. styriaca i. greb., semen) - capsule rigide - cucurbitae peponis seminis extracum spissum (cucurbita pepo l. convar. citrullina i. greb. var. styriaca i. greb., semen) 500.0 mg der: 15-25:1 auszugsmittel ethanolum 92% (m/m), silica hydrophobica colloidalis, kapselhülle: gelatina, e 172 (nigrum), e 172 (rubrum), e 172 (flavum), pro capsula. - traditionsgemäss zur linderung von symptomen der unteren harnwege, die infolge einer überaktiven blase oder blasenschwäche oder einer gutartigen vergrösserung der prostata auftreten - phytoarzneimittel

Itaalia - itaalia - Ministero della Salute

mu srl -

Itaalia - itaalia - Ministero della Salute

pharmalife research srl -

Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharma gmbh - sabal extractum ethanolicum spissum - capsule - estratto di sabal ethanolicum di spessore 320 mg der: 8-9.5:1 auszugsmittel etanolo 90% v/v, excipiens per la capsula. - in caso di incipiente prostatabeschwerden - phytoarzneimittel

Euroopa Liit - itaalia - EMA (European Medicines Agency)

bayer ag - darolutamide - prostatica neoplasie, castrazione-resistente - terapia endocrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - prostatica neoplasie, castrazione-resistente - agenti antineoplastici - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatica neoplasie, castrazione-resistente - radiofarmaci terapeutici - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.